Aarkstore Enterprise---indian Diabetes Market Report & Outlook For 2010-2015

With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world

. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future.

In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015.

Unlike Non-Insulins, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin.

Report Highlights

*

A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015.

*

In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share.

*

USVs Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million

*

IMARC expects around 15 new Drugs to be launched in the Non-Insulin Anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV Inhibitor and GLP-1 Agonist classes.

*

The Insulin Market was worth US$ 117 Million in 2009. Abbott was Indias biggest player accounting for 61% of the total sales.

*

Sanofi Aventis Lantus (Insulin Glargine) represented one of the fastest growing drugs in the last five year and registered sales worth nearly 11 Million in 2009

*

The total number of diabetes patients in India is expected to reach 87 Million by 2030. Around 56% of these patients will be from urban regions.

Forecasts: The report provides forecasts on:

*

Number of diabetes patients

*

Diagnosis and treatment rates in India

*

Diabetes market

*

Non-Insulin Anti-diabetics market

*

Glitazones

*

Biguanides

*

Sulphonylureas

*

Alpha-Glycosidase Inhibitors

*

DPP-IV Inhibhitors

*

GLP-1 Agonists

*

Glinides

*

All other Non-Insulin Anti-diabetic classes

*

Insulin market

For more information please contact :

http://www.aarkstore.com/reports/Indian-Diabetes-Market-Report-Outlook-For-2010-2015-65419.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore Enterprise

POST COMMENT

Branded Content And Its Importance In Sponsorship Marketing Aarkstore Enterprise---china Diabetes Market Report & Outlook For 2010-2015 Career Advice For Graduates: How To Find A Job In Todays Market Aarkstore Enterprise---india Water Purifier Market Outlook 2014 Aarkstore Enterprise---india Power Market Outlook & Forecast 2014 Aarkstore Enterprise---poland Medical Tourism Market 2013 Aarkstore Enterprise---global Cloud Computing Services Market Outlook Social Media Marketing Company: Harnessing Social Media To Promote Your Brand Affiliate Marketing Is One Of The Best Ways To Make Money Online The Everlasting Thrills Of Bebo Kobo Market Aarkstore Enterprise---market Opportunity: Service Delivery Platforms (sdp) Tablet Pc Is Hard To Replace The Notebook Market Position Aarkstore Enterprise---service Delivery Platform (sdp) Solutions And Market Opportunities